For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The closing price of Ginkgo Bioworks Holdings Inc (NYSE: DNA) was $12.05 for the day, down -3.98% from the previous closing price of $12.55. In other words, the price has decreased by -$3.98 from its previous closing price. On the day, 1.2 million shares were traded. DNA stock price reached its highest trading level at $12.71 during the session, while it also had its lowest trading level at $12.0.
Ratios:
Our analysis of DNA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.41 and its Current Ratio is at 5.41. In the meantime, Its Debt-to-Equity ratio is 0.70 whereas as Long-Term Debt/Eq ratio is at 0.70.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 06 ’25 when Che Austin bought 2,200 shares for $14.10 per share.
Coen Steven P. sold 1,084 shares of DNA for $10,669 on Jul 17 ’25. The insider now owns 10,679 shares after completing the transaction at $9.84 per share. On Jul 17 ’25, another insider, Dmytruk Mark E., who serves as the Officer of the company, bought 640 shares for $9.84 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNA now has a Market Capitalization of 742957248 and an Enterprise Value of 622734144. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.93 while its Price-to-Book (P/B) ratio in mrq is 1.03. Its current Enterprise Value per Revenue stands at 2.698 whereas that against EBITDA is -2.698.
Stock Price History:
The Beta on a monthly basis for DNA is 1.51, which has changed by 0.6002656 over the last 52 weeks, in comparison to a change of 0.14460516 over the same period for the S&P500. Over the past 52 weeks, DNA has reached a high of $16.85, while it has fallen to a 52-week low of $5.00. The 50-Day Moving Average of the stock is 4.25%, while the 200-Day Moving Average is calculated to be 25.86%.
Shares Statistics:
DNA traded an average of 1.54M shares per day over the past three months and 1586670 shares per day over the past ten days. A total of 43.82M shares are outstanding, with a floating share count of 40.51M. Insiders hold about 27.92% of the company’s shares, while institutions hold 58.36% stake in the company. Shares short for DNA as of 1753920000 were 8249814 with a Short Ratio of 5.35, compared to 1751241600 on 12019948. Therefore, it implies a Short% of Shares Outstanding of 8249814 and a Short% of Float of 17.979999.
Earnings Estimates
Ginkgo Bioworks Holdings Inc (DNA) is presently subject to a detailed evaluation by 3.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$1.27, with high estimates of -$1.17 and low estimates of -$1.36.
Analysts are recommending an EPS of between -$5.16 and -$5.33 for the fiscal current year, implying an average EPS of -$5.25. EPS for the following year is -$4.35, with 3.0 analysts recommending between -$3.51 and -$4.85.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 4 analysts. It ranges from a high estimate of $40M to a low estimate of $37.5M. As of the current estimate, Ginkgo Bioworks Holdings Inc’s year-ago sales were $89.05MFor the next quarter, 4 analysts are estimating revenue of $40.19M. There is a high estimate of $43.7M for the next quarter, whereas the lowest estimate is $37.08M.
A total of 4 analysts have provided revenue estimates for DNA’s current fiscal year. The highest revenue estimate was $181M, while the lowest revenue estimate was $175M, resulting in an average revenue estimate of $177.07M. In the same quarter a year ago, actual revenue was $227.04MBased on 4 analysts’ estimates, the company’s revenue will be $202.57M in the next fiscal year. The high estimate is $210M and the low estimate is $194.9M.
